Partner Institutions:
|
· Central · |
· Open University · · |
· · Royal Holloway, |
PARK is comprised of eight partner HEIs. PARK provides seed funding to early stage projects with commercial potential that can demonstrate prospects of winning third party investment, or realising license income or trading without further PARK support. There are four active funds – the Stimulus fund, POC I fund, POC II fund and PARK II fund. Each fund has its own maximum investment limit; the maximum any one fund may invest in a project is £50,000. The POC II fund is the most recent and funded by the London Development Agency (LDA).
Altogether, PARK has a £3.77 million seed fund, £2 million granted by the LDA, the balance from other sources.
DASH
Partner Institutions:
|
· · University of the Arts · NHS Trust St Marys |
· · National Physical Laboratory |
· · NHS Trust |
The DASH is a consortium between Imperial Innovations, UCL, NPL, RCA, University of the Arts, Hammersmith Hospitals NHS Trust and St Mary's NHS Trust. The DASH fund has no central decision-making committee for proof of concept applications, rather, money is distributed to each institution and the decision regarding which projects to apply Proof of Concept money to is taken by each institutions own technology transfer office.
Partner Institutions:
|
· · |
· · · |
· · · |
Emerald is a consortium of eight London-based Universities. Emerald is a Proof of Concept fund designed to assist staff and students in the partner institutions to explore the potential of their ideas, inventions or designs to the point where realistic judgement as to the commercial opportunities can be made.
Emerald provides proof of concept awards of up to £40,000 for any one project. The Emerald Fund receives just under £1 million in total from the LDA.
Partner Institutions:
|
· Queen Mary, · King’s College, · |
· · Birkbeck, |
· · · |
The Heptagon consortium, which comprises eight partner institutions, was created to encourage commercialisation of technology in the field of life sciences and healthcare.
Heptagon provides Proof of Concept awards for projects up to £75,000 to support the translation of novel and inventive ideas from fundamental research to commercial demonstration. Key project end-points are likely to include proof of principle data packages, animal studies or prototypes, which can add sufficient value to projects to attract licensing deals or investment for a spin-out company.
Heptagon is funded by a £1.75 million grant from the LDA.
In 2006-2007 NHS Innovations